Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 5/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437295 | 0.94 | TSHR (0.45) | TSHRALDH1A1FAAHTHRBCHRM1 | |
| Methacrylic Acid SCHEMBL7860381 | 0.85 | TSHR (0.44) | TSHRALDH1A1THRBCHRM1 | |
| SCHEMBL2540758 | 0.84 | TSHR (0.50) | TSHRALDH1A1FAAHTHRBCHRM1 | |
| SCHEMBL441439 | 0.83 | FAAH (0.47) | TSHRALDH1A1FAAHTHRBCNR1 | |
| SCHEMBL4382526 | 0.83 | TSHR (0.37) | TSHRALDH1A1FAAHTHRB | |
| SCHEMBL29142898 | 0.83 | TSHR (0.37) | TSHRALDH1A1FAAHTHRB | |
| SCHEMBL28409309 | 0.82 | CHRM1 (0.41) | TSHRALDH1A1FAAHCHRM1AKR1A1 | |
| SCHEMBL5079277 | 0.81 | FAAH (0.54) | TSHRALDH1A1FAAHCNR1CNR2 | |
| Methacrylic Acid SCHEMBL27969671 | 0.81 | TSHR (0.38) | TSHRALDH1A1FAAHTHRBCHRM1 | |
| SCHEMBL23494204 | 0.80 | TSHR (0.40) | TSHRALDH1A1FAAHTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820872-B1 | PYRROLO[1,2-B] PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-3583105-B1 | PYRROLO [1,2-B]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023076983-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-3837261-A1 | THIADIAZOLE IRAK4 INHIBITORS | Gilead Sciences, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3837012-A1 | PYRROLO[1,2-B]PYRIDAZINE DERIVATIVES AS IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3837259-A1 | PYRROLO[1,2-B]PYRIDAZINE DERIVATIVES AS IRAK4 INHIBITORS | Gilead Sciences, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3820872-A1 | PYRROLO[1,2-B] PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2021-05-19 | — | — | EP | disclosed |
| WO-2002046181-A2 | ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| EP-1109558-B1 | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | CV THERAPEUTICS INC (US) | 2002-05-22 | — | — | EP | disclosed |
| US-20020052377-A1 | Method for treating angina | CV THERAPEUTICS, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002007716-A2 | METHOD FOR TREATING ANGINA | CV THERAPEUTICS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| US-20020004506-A1 | Sustained release ranolazine formulations | CV THERAPEUTICS, INC. | 2002-01-10 | — | — | US | disclosed |
| WO-2001066093-A2 | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | CV THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| EP-1109558-A2 | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | CV THERAPEUTICS, INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1096937-A2 | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | CV THERAPEUTICS, INC. (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000013686-A2 | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | CV THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000013687-A2 | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | CV THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | TSHR 4640/4885ALDH1A1 1171/4885FAAH 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.